{"id":158219,"date":"2026-11-10T11:06:48","date_gmt":"2026-11-10T11:06:48","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/158219\/"},"modified":"2026-11-10T11:06:48","modified_gmt":"2026-11-10T11:06:48","slug":"ai-and-life-sciences-how-roche-is-making-regulatory-compliance-faster-and-more-efficient-with-veeva","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/158219\/","title":{"rendered":"AI and Life Sciences &#8211; how Roche is making regulatory compliance faster and more efficient with Veeva"},"content":{"rendered":"<p class=\"p1\">Founded in 1896, Roche is the fifth-largest pharmaceutical company in the world by revenue with two major divisions, Pharmaceuticals and Diagnostics. Inevitably as an organization operating in a highly-regulated market, governance and compliance are mission-critical factors for the firm and AI is now playing a large part in automating aspects of this requirement.<\/p>\n<p class=\"p1\">On a wider level, Roche has had what Group CEO Thomas Schinecker characterizes as \u201ca very comprehensive AI strategy\u201d for several years. Part of this centers on the concept of \u2018Everyday AI\u2019, which involves constantly training employees on using AI tools to become more productive:<\/p>\n<p class=\"p1\">We also monitor the usage of these AI tools in our organization, and we see that 75% of our people are very active AI users, so we feel that it helps us to get more productive.<\/p>\n<p class=\"p1\">AI is also used on what he calls \u201cthe re-shape side\u201d of corporate strategy, taking the three main processes of Service, Sales\/Marketing, and R&amp;D and overhauling them with AI to be faster, more effective and more productive. According to Schinecker:<\/p>\n<p class=\"p1\">We map that out and we create certain use cases which we then invest in, in order to get to an acceleration. And we constantly prioritize new use cases so that we are very effective in providing AI tools to accelerate the work that we&#8217;re doing across these processes.<\/p>\n<p>Regulation<\/p>\n<p class=\"p1\">Being faster and more effective are also key objectives when it comes to regulatory compliance and again AI is acting as an enabler here. On the regulatory front line is Joanne Byrne, Head of Global Regulatory Operations, in which role she has responsibility for global regulatory data, digital transformation, and submission excellence across the entire Roche product life cycle.\u00a0<\/p>\n<p class=\"p1\">She admits that when people think about regulatory, they think it&#8217;s slow, it&#8217;s conservative, but she notes that the firm has to deal with regulators around the globe who have different levels of maturity:<\/p>\n<p class=\"p1\">If I look at how we&#8217;re working today and have been working, we&#8217;re still in very much a document-centric world. It takes us quite a lot of time to put a submission together. And then that whole review approval process is elongated because\u00a0 the way we need to work with regulators is we dispatch and wait. And for some of the smaller agencies, they will be looking to approvals at the larger agencies before they&#8217;re going to review and approve a submission.<\/p>\n<p class=\"p1\">So in today&#8217;s world, it takes quite a lot of time from the conception of a change, say, it&#8217;s a technical change or a new indication, to really being able to generate the package that will support that submission and then getting approval globally for that. That&#8217;s where we are today.<\/p>\n<p class=\"p1\">But Roche wants the future to look somewhat different, she pitches:<\/p>\n<p class=\"p1\">We will absolutely move from this document-centric world where we are today and into a far more data-driven future with new regulations such as M16, M4Q(R2), IDMP. This is looking at and really pushing how we structure content and data in a way that will make it much easier to put the submission together, but also for the regulators to review as well and track the data.<\/p>\n<p class=\"p1\">And things will hopefully be faster:<\/p>\n<p class=\"p1\">From a company point of view, like everyone, we&#8217;re looking to accelerate. Our whole aim is to be able to get medicines to patients faster.<\/p>\n<p>Building blocks<\/p>\n<p class=\"p1\">To realize this future, there are some building blocks that need to be in place. Byrne explains, beginning with a basic fundamental:<\/p>\n<p class=\"p1\">We need to ensure our core competencies and our enterprise systems are fit for purpose for us, first off.<\/p>\n<p class=\"p1\">To that end, Roche is coming to the end of a multi-year project program where it has implemented the Vault platform from Veeva, a cloud-based, multi-tenant solution targeted at the Life Sciences market, providing a single, enterprise-grade environment for managing documents, data, and processes across clinical, regulatory, quality, safety, and commercial domains.<\/p>\n<p class=\"p1\">Everybody is now working in the same systems, says Byrne:<\/p>\n<p class=\"p1\">What we&#8217;re wanting to do in the future is ensure full connectivity of those Vaults. We want data flowing through the Vaults and have more data-driven processes in there. We&#8217;ve got to remember, even before we look at digital solutions like AI, we shouldn&#8217;t under-estimate what it takes to keep these core competencies up to date and fit for purpose for us.<\/p>\n<p class=\"p1\">The Veeva Vault is evolving constantly, she notes, which meets her needs:\u00a0<\/p>\n<p class=\"p1\">Regulations are constantly changing, and our ways of working are constantly changing. From my point of view, I&#8217;m looking at, how do I ensure the sustainment and optimization of our core processes and systems is adequate to meet our future needs?<\/p>\n<p class=\"p1\">Now a lot of the firm\u2019s data and documents live in the Veeva Vault, she says :<\/p>\n<p class=\"p1\">One of the reasons we wanted to be an early adopter [was to explore] could Veeva bring an innovation engine that is fast, that keeps them up with technology changes, but also is seamlessly integrated into the Vaults? We don&#8217;t have lots of add-ons, and then we simplify our system landscape.<\/p>\n<p class=\"p1\">The first use case here is around health authority questions and answers, she adds:<\/p>\n<p class=\"p1\">This process currently within the Veeva Vault RIM (Regulatory Information Managemnt) is very, very manual and burdensome, so if we can streamline this and make it a lot more efficient, this will help us with making sure that we can connect to that data in the future.<\/p>\n<p>AI incoming<\/p>\n<p class=\"p1\">Once accessibility to correct data is ensured then agentic AI can come into play.\u00a0There\u2019s work going on in this area at the moment, Byrne confirms, again with the aim of streamlining and driving efficiencies in how the organization works:<\/p>\n<p class=\"p1\">We have a big AI program, but I would say the basics come first. We&#8217;ve got to continue to invest in our core competencies and our core systems and our data layer, and then we can get the most out of AI.<\/p>\n<p class=\"p1\">There are some specific aspirations that Roche hopes to meet, she explains:<\/p>\n<p class=\"p1\">Our initial focus is very much on ways of working and driving efficiency. I have to say currently today and using some of the apps that we have, it&#8217;s very time-consuming and burdensome for users. We want to very much improve the user experience in our systems and tools. We want to streamline and reduce the number of clicks people need to do. And with that, then we can drive consistency and quality of data.<\/p>\n<p class=\"p1\">I would really love to get rid of or remove all free text fields because once you have a free text field, then you create issues with data entry and consistency there. So initially, over the next year or two, we&#8217;re looking at how to improve the core processes, our user experience, and our data quality.<\/p>\n<p class=\"p1\">And longer term, she says:<\/p>\n<p class=\"p1\">We\u2019re also looking at getting the most out of our data, how do we use data to provide insights on our regulatory strategies and our risk profiles?\u00a0How do we really streamline and accelerate our submission generation? So we have a number of experiments ongoing on that side as well. But initially, it&#8217;s very much around driving that efficiency and quality of data.<\/p>\n<p class=\"p1\">It is a time of experimentation with what\u2019s possible,\u00a0 concludes Byrne:<\/p>\n<p class=\"p1\">When I look at how we have approached this, we&#8217;re in a very revolutionary time. This is a very different way of working. We&#8217;ve made some mistakes, but also technology is moving really fast, so we want to make sure we get the best out of the solutions we have.<\/p>\n","protected":false},"excerpt":{"rendered":"Founded in 1896, Roche is the fifth-largest pharmaceutical company in the world by revenue with two major divisions,&hellip;\n","protected":false},"author":2,"featured_media":158220,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[12447,6967,3313,3310,134],"class_list":["post-158219","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-agentic-ai","tag-ai-adoption","tag-audio","tag-regulation","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117591831180792903","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/158219","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=158219"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/158219\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/158220"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=158219"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=158219"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=158219"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}